Latest From Biotech Now

Jim Greenwood Op-Ed: Time to Fund Medical Countermeasures against Threats like Ebola

Jim Greenwood

On Friday, The Hill published an op-ed from BIO President and CEO Jim Greenwood calling on Congressional appropriators to fully fund federal biodefense programs, which partner with industry to develop medical countermeasures against Ebola as well as other threats like smallpox, anthrax, and botulism toxin. President Obama’s supplemental Ebola funding request last week asked Congress to appropriate $157 million in funding for BARDA and $238 million for the National Institutes of Health to support Ebola Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

New Survey: Most women believe they are not up-to-date on vaccinations

TheHill

A new national survey from Rite Aid (NYSE: RAD) and National Foundation for Infectious Diseases (NFID) shows that the majority of adult women living in the United States do not believe they are up to date on vaccinations to protect against many preventable diseases. Seventy percent of survey participants reported receiving at least one vaccination in the last five years to prevent disease—most often citing the flu and tetanus vaccines. When asked about a range Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

A Preview of the 2015 ARPA-E Energy Innovation Summit, Feb 9-11

arpa-e-logo

The U.S. Department of Energy’s Advanced Research Projects Agency-Energy (ARPA-E) is an innovative and collaborative government agency that brings together America’s best and brightest scientists, engineers, and entrepreneurs. ARPA-E programs are created to address critical challenges in energy innovation, and ARPA-E-funded project teams receive hands-on guidance to meet ambitious milestones that push the boundaries of energy innovation and help move their technologies into the marketplace. Now in its sixth year, The ARPA-E Energy Innovation Summit is Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , ,

2015 BIO CEO & Investor Conference™ to Feature Dynamic List of Company Presentations

CEO-BuzzofBIO

Past and future attendees of the annual BIO CEO & Investor Conference have high expectations for the caliber of company’s chosen to present at the event. Presenting companies are hand selected for the event and consist of a selection of mid to large cap established public companies from around the globe who typically have a clinical stage program centered on therapeutics, molecular diagnostics, or a platform technology, as well as an upcoming clinical, regulatory or Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Nature Biotechnology: Outpaced by an outbreak

admin-ajax

The current issue of Nature Biotechnology contains an editorial on the response to the Ebola outbreak that is well-worth the read. The editors discuss some of the barriers which have slowed the development of Ebola medicines, including budgetary issues with federal programs designed to incentivize the development of medical countermeasures for threats like Ebola: We have no medicines to combat Ebola partly because of the time it takes to develop products—BARDA has been in existence Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,